Clinical efficacy of desmopressin in the treatment of mild hemophilia A in children.
- Author:
Song-Ting BAI
1
;
Jie LU
;
Guang-Yao SHENG
;
Song-Tao XU
;
Lei XIE
;
Shao PENG
Author Information
- Publication Type:Journal Article
- MeSH: Child; Child, Preschool; Deamino Arginine Vasopressin; therapeutic use; Factor VIII; analysis; Hemophilia A; blood; drug therapy; Humans; Infant; Male; Partial Thromboplastin Time
- From: Chinese Journal of Contemporary Pediatrics 2011;13(9):715-717
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the effects of desmopressin (DDAVP) on coagulation factor Ⅷ (FⅧ) and activated partial thromboplastin time (APTT) in children with mild hemophilia A.
METHODSEighteen children with mild hemophilia A were enrolled. DDAVP (0.3 μg/kg•d) was injected intravenously for 5 days. Plasma FⅧ levels and APTT were measured before and after DDAVP treatment.
RESULTSIn 16 of 18 children with mild hemophilia A, the bleeding symptoms, including the articular or musclar hematoma, were significantly alleviated as a result of DDAVP treatment. The plasma FⅧ levels increased significantly to (27±4)% and APTT was shortened to (66±10)s 60 minutes after the first dose of DDAVP treatment. The plasma FⅧ remained at the levels of 25%-30% during 3-4 days of DDAVP treatment. Five days after DDAVP treatment, the plasma FⅧ levels decreased [(21±3)%], and APTT was prolonged when compared with 1-4 days of DDAVP treatment.
CONCLUSIONSDDAVP treatment can increase plasma FⅧ levels and shorten APTT in children with mild hemophilia A. DDAVP is effective in the treatment of mild hemophilia A. The duration of DDAVP therapy for mild hemophilia A is recommended as 3 to 4 days.
